{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T09:25:31Z","timestamp":1762507531934},"reference-count":55,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2018,10,4]],"date-time":"2018-10-04T00:00:00Z","timestamp":1538611200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,9,20]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Immune checkpoint inhibitors such as antibodies to cytotoxic lymphocyte-associated protein 4 (ipilimumab) and programmed cell-death 1 (pembrolizumab, nivolumab) molecules have been used in non-small cell lung cancer, metastatic melanoma, and renal-cell carcinoma, among others. With these agents, immune-related adverse events (irAEs) can occur, including those affecting the neurological axis. In this review, high-grade neurological irAEs associated with immune checkpoint inhibitors including cases of Guillain-Barr\u00e9 syndrome (GBS) and myasthenia gravis (MG) are analyzed. Based on current literature and experience at our institution with 4 cases of high-grade neurological irAEs associated with immune checkpoint inhibitors (2 cases of GBS, 1 case of meningo-radiculitis, and 1 case of myelitis), we propose an algorithm for the investigation and treatment of high-grade neurological irAEs. Our algorithm incorporates both peripheral nervous system (meningo-radiculitis, GBS, MG) and central nervous system presentations (myelitis, encephalopathy). It is anticipated that our algorithm will be useful both to oncologists and neurologists who are likely to encounter neurological irAEs more frequently in the future as immune checkpoint inhibitors become more widely used.<\/jats:p>","DOI":"10.1093\/nop\/npy039","type":"journal-article","created":{"date-parts":[[2018,10,4]],"date-time":"2018-10-04T05:42:53Z","timestamp":1538631773000},"page":"340-345","source":"Crossref","is-referenced-by-count":5,"title":["Proposed diagnostic and treatment paradigm for high-grade neurological complications of immune checkpoint inhibitors"],"prefix":"10.1093","volume":"6","author":[{"given":"Dustin","family":"Anderson","sequence":"first","affiliation":[{"name":"Department of Medicine (Neurology), University of Alberta, Edmonton, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Grayson","family":"Beecher","sequence":"additional","affiliation":[{"name":"Department of Medicine (Neurology), University of Alberta, Edmonton, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nabeela","family":"Nathoo","sequence":"additional","affiliation":[{"name":"Department of Medicine (Neurology), University of Alberta, Edmonton, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Smylie","sequence":"additional","affiliation":[{"name":"Department of Oncology (Medical Oncology), University of Alberta, Edmonton, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer A","family":"McCombe","sequence":"additional","affiliation":[{"name":"Department of Medicine (Neurology), University of Alberta, Edmonton, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Walker","sequence":"additional","affiliation":[{"name":"Department of Oncology (Medical Oncology), University of Alberta, Edmonton, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rajive","family":"Jassal","sequence":"additional","affiliation":[{"name":"Department of Medicine (Neurology), University of Alberta, Edmonton, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2018,10,4]]},"reference":[{"issue":"4","key":"2020013109271580000_CIT0001","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat Rev Cancer"},{"issue":"6","key":"2020013109271580000_CIT0002","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1038\/nri2326","article-title":"Inhibitory B7-family molecules in the tumour microenvironment","volume":"8","author":"Zou","year":"2008","journal-title":"Nat Rev Immunol"},{"issue":"11","key":"2020013109271580000_CIT0003","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1038\/ni1102-991","article-title":"Cancer immunoediting: from immunosurveillance to tumor escape","volume":"3","author":"Dunn","year":"2002","journal-title":"Nat Immunol"},{"issue":"19","key":"2020013109271580000_CIT0004","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1056\/NEJMoa1510665","article-title":"Nivolumab versus everolimus in advanced renal-cell carcinoma","volume":"373","author":"Motzer","year":"2015","journal-title":"N Engl J Med"},{"issue":"17","key":"2020013109271580000_CIT0005","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","article-title":"Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer","volume":"373","author":"Borghaei","year":"2015","journal-title":"N Engl J Med"},{"issue":"21","key":"2020013109271580000_CIT0006","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1056\/NEJMoa1501824","article-title":"Pembrolizumab for the treatment of non-small-cell lung cancer","volume":"372","author":"Garon","year":"2015","journal-title":"N Engl J Med"},{"issue":"3","key":"2020013109271580000_CIT0007","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/S1470-2045(15)70054-9","article-title":"Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial","volume":"16","author":"Rizvi","year":"2015","journal-title":"Lancet Oncol"},{"issue":"5","key":"2020013109271580000_CIT0008","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/S1470-2045(15)70122-1","article-title":"Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial","volume":"16","author":"Eggermont","year":"2015","journal-title":"Lancet Oncol"},{"issue":"2","key":"2020013109271580000_CIT0009","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1056\/NEJMoa1305133","article-title":"Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma","volume":"369","author":"Hamid","year":"2013","journal-title":"N Engl J Med"},{"issue":"8","key":"2020013109271580000_CIT0010","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N Engl J Med"},{"issue":"1","key":"2020013109271580000_CIT0011","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined nivolumab and ipilimumab or monotherapy in untreated melanoma","volume":"373","author":"Larkin","year":"2015","journal-title":"N Engl J Med"},{"issue":"4","key":"2020013109271580000_CIT0012","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S1470-2045(15)70076-8","article-title":"Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial","volume":"16","author":"Weber","year":"2015","journal-title":"Lancet Oncol"},{"key":"2020013109271580000_CIT0013","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejca.2016.12.001","article-title":"Neurological adverse events associated with immune checkpoint inhibitors: review of the literature","volume":"73","author":"Cuzzubbo","year":"2017","journal-title":"Eur J Cancer"},{"issue":"2","key":"2020013109271580000_CIT0014","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1097\/CJI.0b013e318193a206","article-title":"Inflammatory enteric neuropathy with severe constipation after ipilimumab treatment for melanoma: a case report","volume":"32","author":"Bhatia","year":"2009","journal-title":"J Immunother"},{"issue":"4","key":"2020013109271580000_CIT0015","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1007\/s00408-015-9716-8","article-title":"Severe acute orthopnea: ipilimumab-induced bilateral phrenic nerve neuropathy","volume":"193","author":"Jinnur","year":"2015","journal-title":"Lung"},{"issue":"2","key":"2020013109271580000_CIT0016","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1097\/CJI.0000000000000070","article-title":"Peripheral neuropathy associated with ipilimumab: a report of 2 cases","volume":"38","author":"Thaipisuttikul","year":"2015","journal-title":"J Immunother"},{"issue":"12","key":"2020013109271580000_CIT0017","doi-asserted-by":"crossref","first-page":"E69","DOI":"10.3174\/ajnr.A4581","article-title":"Ipilimumab therapy for melanoma: a mimic of leptomeningeal metastases","volume":"36","author":"Ali","year":"2015","journal-title":"AJNR Am J Neuroradiol"},{"issue":"6","key":"2020013109271580000_CIT0018","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1007\/s10637-011-9787-1","article-title":"Severe meningo-radiculo-neuritis associated with ipilimumab","volume":"30","author":"Bompaire","year":"2012","journal-title":"Invest New Drugs"},{"issue":"6","key":"2020013109271580000_CIT0019","doi-asserted-by":"crossref","first-page":"e32","DOI":"10.1200\/JCO.2013.49.7735","article-title":"Antitumor granuloma formation by CD4+ T cells in a patient with rapidly progressive melanoma experiencing spiking fevers, neuropathy, and other immune-related toxicity after treatment with ipilimumab","volume":"33","author":"Luke","year":"2015","journal-title":"J Clin Oncol"},{"issue":"3","key":"2020013109271580000_CIT0020","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1002\/mus.23830","article-title":"Multifocal radiculoneuropathy during ipilimumab treatment of melanoma","volume":"48","author":"Manousakis","year":"2013","journal-title":"Muscle Nerve"},{"issue":"5","key":"2020013109271580000_CIT0021","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1177\/0194599815606701","article-title":"Bilateral facial palsy following ipilimumab infusion for melanoma","volume":"153","author":"Altman","year":"2015","journal-title":"Otolaryngol Head Neck Surg"},{"issue":"4","key":"2020013109271580000_CIT0022","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1136\/practneurol-2012-000447","article-title":"Neurological immune-related adverse events of ipilimumab","volume":"13","author":"Bot","year":"2013","journal-title":"Pract Neurol"},{"issue":"1","key":"2020013109271580000_CIT0023","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1097\/CJI.0b013e31827807dd","article-title":"A severe case of ipilimumab-induced Guillain-Barr\u00e9 syndrome revealed by an occlusive enteric neuropathy: a differential diagnosis for ipilimumab-induced colitis","volume":"36","author":"Gaudy-Marqueste","year":"2013","journal-title":"J Immunother"},{"issue":"2","key":"2020013109271580000_CIT0024","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1097\/CND.0000000000000193","article-title":"Guillain-Barr\u00e9 syndrome triggered by immune checkpoint inhibitors: a case report and literature review","volume":"19","author":"Supakornnumporn","year":"2017","journal-title":"J Clin Neuromuscul Dis"},{"issue":"4","key":"2020013109271580000_CIT0025","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1093\/annonc\/mdr028","article-title":"Anti-CTLA-4 antibody-induced Guillain-Barr\u00e9 syndrome in a melanoma patient","volume":"22","author":"Wilgenhof","year":"2011","journal-title":"Ann Oncol"},{"issue":"5","key":"2020013109271580000_CIT0026","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1002\/acn3.547","article-title":"Seronegative antibody-mediated neurology after immune checkpoint inhibitors","volume":"5","author":"Wilson","year":"2018","journal-title":"Ann Clin Transl Neurol"},{"issue":"50","key":"2020013109271580000_CIT0027","doi-asserted-by":"crossref","first-page":"e9262","DOI":"10.1097\/MD.0000000000009262","article-title":"Coexisting myasthenia gravis, myositis, and polyneuropathy induced by ipilimumab and nivolumab in a patient with non-small-cell lung cancer: a case report and literature review","volume":"96","author":"Chen","year":"2017","journal-title":"Medicine (Baltimore)"},{"issue":"27","key":"2020013109271580000_CIT0028","doi-asserted-by":"crossref","first-page":"e7350","DOI":"10.1097\/MD.0000000000007350","article-title":"Nivolumab-induced myasthenia gravis in a patient with squamous cell lung carcinoma: case report","volume":"96","author":"Chen","year":"2017","journal-title":"Medicine (Baltimore)"},{"issue":"33","key":"2020013109271580000_CIT0029","doi-asserted-by":"crossref","first-page":"e122","DOI":"10.1200\/JCO.2013.51.1683","article-title":"Myasthenia gravis induced by ipilimumab in patients with metastatic melanoma","volume":"33","author":"Johnson","year":"2015","journal-title":"J Clin Oncol"},{"issue":"4","key":"2020013109271580000_CIT0030","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1093\/neuonc\/nou001","article-title":"Atypical neurological complications of ipilimumab therapy in patients with metastatic melanoma","volume":"16","author":"Liao","year":"2014","journal-title":"Neuro Oncol"},{"issue":"2","key":"2020013109271580000_CIT0031","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1002\/mus.24648","article-title":"Myasthenia gravis associated with ipilimumab and nivolumab in the treatment of small cell lung cancer","volume":"52","author":"Loochtan","year":"2015","journal-title":"Muscle Nerve"},{"key":"2020013109271580000_CIT0032","doi-asserted-by":"crossref","first-page":"150","DOI":"10.3389\/fneur.2018.00150","article-title":"Myasthenia gravis induced by ipilimumab in a patient with metastatic melanoma","volume":"9","author":"Montes","year":"2018","journal-title":"Front Neurol"},{"issue":"1","key":"2020013109271580000_CIT0033","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1093\/jjco\/hyv158","article-title":"Acetylcholine receptor binding antibody-associated myasthenia gravis and rhabdomyolysis induced by nivolumab in a patient with melanoma","volume":"46","author":"Shirai","year":"2016","journal-title":"Jpn J Clin Oncol"},{"issue":"11","key":"2020013109271580000_CIT0034","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1212\/WNL.0000000000004359","article-title":"Nivolumab-related myasthenia gravis with myositis and myocarditis in Japan","volume":"89","author":"Suzuki","year":"2017","journal-title":"Neurology"},{"issue":"12","key":"2020013109271580000_CIT0035","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1159\/000368316","article-title":"Late-onset paraplegia after complete response to two cycles of ipilimumab for metastatic melanoma","volume":"37","author":"O\u2019Kane","year":"2014","journal-title":"Oncol Res Treat"},{"issue":"6","key":"2020013109271580000_CIT0036","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1634\/theoncologist.2016-0487","article-title":"Neurologic serious adverse events associated with nivolumab plus ipilimumab or nivolumab alone in advanced melanoma, including a case series of encephalitis","volume":"22","author":"Larkin","year":"2017","journal-title":"Oncologist"},{"issue":"6","key":"2020013109271580000_CIT0037","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1097\/MAJ.0000000000000584","article-title":"Meningoencephalitis following ipilimumab administration in metastatic melanoma","volume":"350","author":"Stein","year":"2015","journal-title":"Am J Med Sci"},{"issue":"6","key":"2020013109271580000_CIT0038","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1158\/2326-6066.CIR-15-0035","article-title":"Ipilimumab-induced encephalopathy with a reversible splenial lesion","volume":"3","author":"Conry","year":"2015","journal-title":"Cancer Immunol Res"},{"issue":"5","key":"2020013109271580000_CIT0039","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1177\/1352458514549403","article-title":"Severe relapse in a multiple sclerosis patient associated with ipilimumab treatment of melanoma","volume":"21","author":"Gettings","year":"2015","journal-title":"Mult Scler"},{"issue":"3","key":"2020013109271580000_CIT0040","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1158\/2326-6066.CIR-15-0186","article-title":"Eosinophilic fasciitis and acute encephalopathy toxicity from pembrolizumab treatment of a patient with metastatic melanoma","volume":"4","author":"Khoja","year":"2016","journal-title":"Cancer Immunol Res"},{"issue":"1","key":"2020013109271580000_CIT0041","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1177\/1078155215620922","article-title":"Posterior reversible encephalopathy syndrome following pembrolizumab therapy for relapsed Hodgkin\u2019s lymphoma","volume":"23","author":"LaPorte","year":"2017","journal-title":"J Oncol Pharm Pract"},{"key":"2020013109271580000_CIT0042","doi-asserted-by":"crossref","first-page":"108","DOI":"10.3389\/fimmu.2018.00108","article-title":"Fatal necrotizing encephalopathy after treatment with nivolumab for squamous non-small cell lung cancer: case report and review of the literature","volume":"9","author":"Leitinger","year":"2018","journal-title":"Front Immunol"},{"issue":"1-2","key":"2020013109271580000_CIT0043","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.jns.2014.06.023","article-title":"Lambrolizumab induced central nervous system (CNS) toxicity","volume":"344","author":"Mandel","year":"2014","journal-title":"J Neurol Sci"},{"issue":"12","key":"2020013109271580000_CIT0044","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1158\/2326-6066.CIR-15-0141","article-title":"Subacute CNS demyelination after treatment with nivolumab for melanoma","volume":"3","author":"Maurice","year":"2015","journal-title":"Cancer Immunol Res"},{"issue":"11","key":"2020013109271580000_CIT0045","doi-asserted-by":"crossref","first-page":"2923","DOI":"10.1093\/brain\/aww225","article-title":"CTLA4 blockade elicits paraneoplastic neurological disease in a mouse model","volume":"139","author":"Yshii","year":"2016","journal-title":"Brain"},{"issue":"1","key":"2020013109271580000_CIT0046","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s11910-018-0810-1","article-title":"Neurological adverse events associated with immune checkpoint inhibitors: diagnosis and management","volume":"18","author":"Astaras","year":"2018","journal-title":"Curr Neurol Neurosci Rep"},{"issue":"6","key":"2020013109271580000_CIT0047","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1097\/WCO.0000000000000391","article-title":"Neurologic complications of immune checkpoint inhibitors","volume":"29","author":"Hottinger","year":"2016","journal-title":"Curr Opin Neurol"},{"issue":"6","key":"2020013109271580000_CIT0048","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1097\/WCO.0000000000000503","article-title":"Neurological toxicities associated with immune-checkpoint inhibitors","volume":"30","author":"Touat","year":"2017","journal-title":"Curr Opin Neurol"},{"issue":"5","key":"2020013109271580000_CIT0049","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/j.amjoto.2018.06.003","article-title":"Immune checkpoint-mediated myositis and myasthenia gravis: a case report and review of evaluation and management","volume":"39","author":"Kang","year":"2018","journal-title":"Am J Otolaryngol"},{"issue":"2","key":"2020013109271580000_CIT0050","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1097\/CMR.0000000000000310","article-title":"Two cases of clinical myasthenia gravis associated with pembrolizumab use in responding melanoma patients","volume":"27","author":"Nguyen","year":"2017","journal-title":"Melanoma Res"},{"key":"2020013109271580000_CIT0051","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.jneuroim.2016.12.016","article-title":"Autoimmune limbic encephalitis with anti-contactin-associated protein-like 2 antibody secondary to pembrolizumab therapy","volume":"305","author":"Brown","year":"2017","journal-title":"J Neuroimmunol"},{"issue":"10","key":"2020013109271580000_CIT0052","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/S1474-4422(08)70215-1","article-title":"Clinical features, pathogenesis, and treatment of Guillain-Barr\u00e9 syndrome","volume":"7","author":"van Doorn","year":"2008","journal-title":"Lancet Neurol"},{"issue":"6","key":"2020013109271580000_CIT0053","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1212\/WNL.61.6.736","article-title":"Practice parameter: immunotherapy for Guillain-Barr\u00e9 syndrome: report of the Quality Standards Subcommittee of the American Academy of Neurology","volume":"61","author":"Hughes","year":"2003","journal-title":"Neurology"},{"issue":"4","key":"2020013109271580000_CIT0054","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1212\/WNL.0000000000002790","article-title":"International consensus guidance for management of myasthenia gravis: executive summary","volume":"87","author":"Sanders","year":"2016","journal-title":"Neurology"},{"issue":"24","key":"2020013109271580000_CIT0055","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1212\/WNL.0b013e31823dc535","article-title":"Evidence-based guideline: clinical evaluation and treatment of transverse myelitis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology","volume":"77","author":"Scott","year":"2011","journal-title":"Neurology"}],"container-title":["Neuro-Oncology Practice"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/nop\/article-pdf\/6\/5\/340\/32303209\/npy039.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/nop\/article-pdf\/6\/5\/340\/32303209\/npy039.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,1,31]],"date-time":"2020-01-31T09:28:11Z","timestamp":1580462891000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/nop\/article\/6\/5\/340\/5115269"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10,4]]},"references-count":55,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2018,10,4]]},"published-print":{"date-parts":[[2019,9,20]]}},"URL":"https:\/\/doi.org\/10.1093\/nop\/npy039","relation":{},"ISSN":["2054-2577","2054-2585"],"issn-type":[{"value":"2054-2577","type":"print"},{"value":"2054-2585","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,10]]},"published":{"date-parts":[[2018,10,4]]}}}